FDA Reviewers Criticize Replimune Data Amid Muted Investor Reaction

Replimune shares plummeted 40% on concerns FDA scientists are still skeptical of its melanoma drug.^{[6190728][6194059]} Meanwhile, ProMIS Therapeutics saw a surge in stock price after announcing promising results for its Alzheimer's disease treatment.^{[6190728][6194059]} The FDA reviewers' criticism of Replimune's data has raised concerns about the company's ability to secure approval for its melanoma treatment.^{[6190728][6194059]}